Pathology & Oncology Research

, 11:139 | Cite as

Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function

Article
Received:
Accepted:

Abstract

The most common complaints of cancer patients undergoing chemoor radiotherapy are fatigue, nausea, vomiting, malaise, diarrhea and headaches. These adverse effects are thought to be due to damage of normal tissues during the course of therapy. In addition, recent evidence indicates that fatigue is related to reduced mitochondrial function through loss of efficiency in the electron transport chain caused by membrane oxidation, and this occurs during aging, in fatiguing illnesses and in cancer patients during cytotoxic therapy. Lipid Replacement Therapy administered as a nutritional supplement with antioxidants can prevent oxidative membrane damage to normal tissues, restore mitochondrial and other cellular membrane functions and reduce the adverse effects of cancer therapy. Recent clinical trials using patients with chronic fatigue have shown the benefit of Lipid Replacement Therapy plus antioxidants in restoring mitochondrial electron transport function and reducing moderate to severe chronic fatigue by protecting mitochondrial and other cellular membranes from oxidative and other damage. In cancer patients a placebo-controlled, cross-over clinical trial using Lipid Replacement Therapy plus antioxidants demonstrated that the adverse effects of chemotherapy can be reduced in 57–70% of patients. Dietary use of unoxidized membrane lipids plus antioxidants is recommended for patients undergoing cancer therapy to improve quality of life but should not be taken at the same time of day as the therapy.

Key words

lipids antioxidants cancer therapy dietary supplement fatigue mitochondria 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Buckingham R, Fitt J, Sitzia J: Patients’ experience of chemotherapy: side-effects of carboplatin in the treatment of carcinoma of the ovary. Eur J Cancer Care 6: 59–71, 1997.CrossRefGoogle Scholar
  2. 2.
    Vogelzang N, Breitbart W, Cella D, et al: Patient caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semiu Hematol 34 (Suppl 2): 4–12, 1997.Google Scholar
  3. 3.
    Romanelli A, Bozzone A, Magrone G, et al: Cancer-related fatigue: evaluation and treatment. Rays 29: 453–455, 2004.PubMedGoogle Scholar
  4. 4.
    Bender CM, Ergyn FS, Rosenzweig MQ, et al: Symptom clusters in breast cancer across 3 phases of the disease. Cancer Nurs 28: 219–225, 2005.PubMedCrossRefGoogle Scholar
  5. 5.
    Ahlberg K, Ekman T, Gaston-Johansson F: Fatigue, psychological distress, coping resources, and functional status during radiotherapy for uterine cancer. Oncol Nurs Forum 32: 633–640, 2005.PubMedCrossRefGoogle Scholar
  6. 6.
    Shafqat A, Einhorn LH, Hanna N, et al: Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment (dagger). Ann Oncol 16: 1545–1550, 2005.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu L, Marler MR, Parker BA, et al: The relationship between fatigue and light exposure during chemotherapy. Support Care Cancer in press, 2005.Google Scholar
  8. 8.
    Von Roenn JH, Paice JA: Control of common, non-pain cancer symptoms. Semin Oncol 32: 200–210, 2005.CrossRefGoogle Scholar
  9. 9.
    Kroenke K, Wood DR, Mangelsdorff AD, et al: Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA 260: 929–934, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Morrison JD: Fatigue as a presenting complaint in family practice. J Family Pract 10: 795–801, 1980.Google Scholar
  11. 11.
    McDonald E, David AS, Pelosi AJ, Mann AH: Chronic fatigue in primary care attendees. Psychol Med 23: 987–998, 1993.PubMedCrossRefGoogle Scholar
  12. 12.
    Piper BF, Linsey AM, Dodd MJ: Fatigue mechanism in cancer. Oncol Nursing Forum 14: 17–23, 1987.Google Scholar
  13. 13.
    Piper BF, Dribble SL, Dodd MJ, et al: The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nursing Forum 25: 667–684, 1998.Google Scholar
  14. 14.
    Nicolson GL: Lipid replacement as an adjunct to therapy for chronic fatigue, anti-aging and restoration of mitochondrial function. J Am Nutraceut Assoc 6: 22–28, 2003.Google Scholar
  15. 15.
    Huang H, Manton KG: The role of oxidative damage in mitochondria during aging: a review. Front Biosci 9: 1100–1117, 2004.PubMedCrossRefGoogle Scholar
  16. 16.
    Richter C, Par JW, Ames B: Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 85: 6465–6467, 1998.CrossRefGoogle Scholar
  17. 17.
    Wei YH, Lee HC: Oxidative stress, mitochondrial DNA mutation and impairment of antioxidant enzymes in aging. Exp Biol Med 227: 671–682, 2002.Google Scholar
  18. 18.
    Harman D: Aging: A theory based on free radical and radiation chemistry. J Gerontol 2: 298–300, 1956.Google Scholar
  19. 19.
    Halliwell B: Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685–716, 2001.PubMedCrossRefGoogle Scholar
  20. 20.
    Tan, NSS, Vinckenbosch NS, Liu N, et al: Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 22: 5114–5127, 2002.PubMedCrossRefGoogle Scholar
  21. 21.
    Chen D, Cao G, Hastings T, et al: Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. J Neurochem 81: 1273–1284, 2002.PubMedCrossRefGoogle Scholar
  22. 22.
    Xu D, Finkel T: A role for mitochondria as potential regulators of cellular life span. Biochem Biophys Res Commun 294: 245–248, 2002.PubMedCrossRefGoogle Scholar
  23. 23.
    Logan AC, Wong C: Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 6: 450–459, 2001.PubMedGoogle Scholar
  24. 24.
    Manuel y Keenoy B, Moorkens G, Vertommen J, et al: Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 68: 2037–2049, 2001.PubMedCrossRefGoogle Scholar
  25. 25.
    Richards RS, Roberts TK, McGregor NR, et al: Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep 5: 35–41, 2000.PubMedCrossRefGoogle Scholar
  26. 26.
    Felle S, Mecocci P, Fano G, et al: Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radical Biol Med 29: 1252–1259, 2000.CrossRefGoogle Scholar
  27. 27.
    Pall ML: Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypotheses 54: 115–125, 2000.PubMedCrossRefGoogle Scholar
  28. 28.
    Castro L, Rodriguez M, Radi R: Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J Biol Chem 269: 29409–29415, 1994.PubMedGoogle Scholar
  29. 29.
    Radi R, Rodriguez M, Castro L, Telleri R: Inhibition of mitochondrial electronic transport by peroxynitrite. Arch Biochem Biophys 308: 89–95, 1994.PubMedCrossRefGoogle Scholar
  30. 30.
    Manuel y Keenoy B, Moorkens G, Vertommen J, et al: Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. J Am Coll Nutr 19: 374–382, 2000.PubMedGoogle Scholar
  31. 31.
    Kanno T, Sato EE, Muranaka S, et al: Oxidative stress underlies the mechanism for Ca(2+)-induced permeability transition of mitochondria. Free Radical Res 38: 27–35, 2004.CrossRefGoogle Scholar
  32. 32.
    Nicolson GL, Poste G, Ji T: Dynamic aspects of cell membrane organization. Cell Surface Rev 3: 1–73, 1977.Google Scholar
  33. 33.
    Subczynski WK, Wisniewska A: Physical properties of lipid bilayer membranes: relevance to membrane biological functions. Acta Biochim Pol 47: 613–625, 2000.PubMedGoogle Scholar
  34. 34.
    Ellithorpe RR, Settineri R, Nicolson GL: Reduction of fatigue by use of a dietary supplement containing glycophospholipids. J Am Nutraceut Assoc 6: 23–28, 2003.Google Scholar
  35. 35.
    Agadjanyan M, Vasilevko V, Ghochikyan A, et al: Nutritional supplement (NTFactor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Syndr 11: 23–26, 2003.CrossRefGoogle Scholar
  36. 36.
    Hajri T, Abumrad NA: Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu Rev Nutr 22: 383–415, 2002.PubMedCrossRefGoogle Scholar
  37. 37.
    Hamilton JA: Fatty acid transport: difficult or easy? J Lipid Res 39: 467–481, 1998.PubMedGoogle Scholar
  38. 38.
    Fellmann P, Herve P, Pomorski T, et al: Transmembrane movement of diether phospholipids in human erythrocytes and human fibroblasts. Biochemistry 39: 4994–5003, 2000.PubMedCrossRefGoogle Scholar
  39. 39.
    Conner SD, Schmid SL: Regulated portals of entry into the cell. Nature 422: 37–44, 2003.PubMedCrossRefGoogle Scholar
  40. 40.
    Mansbach CM, Dowell R: Effect of increasing lipid loads on the ability of the endoplasmic reticulum to transport lipid to the Golgi. J Lipid Res 41: 605–612, 2000.PubMedGoogle Scholar
  41. 41.
    De AK, Darad R: Age-associated changes in antioxidants and antioxidative enzymes in rats. Mech Ageing Dev 59: 123–128, 1991.PubMedCrossRefGoogle Scholar
  42. 42.
    Ames BM: Micronutrients prevent cancer and delay aging. Toxicol Lett 102: 1035–1038, 1998.CrossRefGoogle Scholar
  43. 43.
    Sharman EH, Bondy SC: Effects of age and dietary antioxidants on cerebral electron transport chain activity. Neurobiol Aging 22: 629–634, 2001.PubMedCrossRefGoogle Scholar
  44. 44.
    Sugiyama S, Yamada K, Ozawa T: Preservation of mitochondrial respiratory function by coenzyme Q10 in aged rat skeletal muscle. Biochem Mol Biol Int 37: 1111–1120, 1995.PubMedGoogle Scholar
  45. 45.
    Lin MT, Simon DK, Ahn CH, et al: High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer’s disease brain. Hum Mol Genet 11: 133–145, 2002.PubMedCrossRefGoogle Scholar
  46. 46.
    Seidman M, Khan MJ, Tang WX, Quirk WS: Influence of lecithin on mitochondrial DNA and age-related hearing loss. Otolaryngol Head Neck Surg 127: 138–144, 2002.PubMedCrossRefGoogle Scholar
  47. 47.
    Miquel J: Can antioxidant diet supplementation protect against age-related mitochondrial damage? Ann NY Acad Sci 959: 317–347, 2002.Google Scholar
  48. 48.
    Nicolson GL, Ellithorpe R: Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. J Chronic Fatigue Syndr, in press, 2005.Google Scholar
  49. 49.
    Colodny L, Lynch K, Farber C, et al: Results of a study to evaluate the use of Propax to reduce adverse effects of chemotherapy. J Am Nutraceut Assoc 2: 17–25, 2000.Google Scholar

Copyright information

© Arányi Lajos Foundation 2005

Authors and Affiliations

  1. 1.Department of Molecular PathologyThe Institute for Molecular MedicineHuntington Beach

Personalised recommendations